dc.date.accessioned | 2018-06-08T14:00:24Z | |
dc.date.issued | 2013-02 | |
dc.identifier | 2 | |
dc.identifier.citation | ANTICANCER RESEARCH, 2013, 33 pp. 371 - 377 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/1766 | |
dc.description.abstract | Background: Fascin-1 (FSCN1) plays an important role in cancer development and is associated with invasion and metastasis. Therefore, we explored the expression and localization of FSCN1 in epithelial ovarian cancer (EOC). Materials and Methods: Expression analysis was performed by immunohistochemistry of paraffin-embedded tumor samples from 89 patients with EOC. Staining intensity and the percentage of positively stained tumor cells were used to calculate an immunoreactive score of 0-12 (IRS). These results were correlated to clinical and pathological characteristics as well as to patient survival. Results: Negative (IRS=0), weak (IRS=0-2) and strong (IRS\ensuremath>2) expression of FSCN1 in EOC was found in 5 (5.6%), 30 (33.7%) and 54 (60.7%) tumor samples, respectively. There was a strong correlation of residual postoperative tumor of \ensuremath>1 cm with higher immunoexpression of FSCNI (p=0.04). Lower FSCN1 expression was associated with significantly poorer overall survival (p=0.02). Conclusion: FSCN1 is frequently expressed in primary EOC. Its prognostic impact and function remains inconclusive and should be further examined in larger trials. | |
dc.format.extent | 371 - 377 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.title | Prognostic Impact of Fascin-1 (FSCN1) in Epithelial Ovarian Cancer | |
dc.type | Journal Article | |
rioxxterms.licenseref.startdate | 2013-02 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | ANTICANCER RESEARCH | |
pubs.notes | ISI Document Delivery No.: 096SG Times Cited: 0 Cited Reference Count: 31 Hanker, Lars C. Karn, Thomas Holtrich, Uwe Graeser, Monika Becker, Sven Reinhard, Joscha Ruckhaeberle, Eugen Gevensleben, Heidrun Rody, Achim Held-Hecker foundation, Frankfurt, Germany We thank Samira Adel and Ekatherini Brinkmann for expert technical assistance. This work was supported by grants from Held-Hecker foundation, Frankfurt, Germany. Int inst anticancer research Athens keywords: Fascin-1 ovarian cancer expression prognosis immunohistochemistry actin-bundling protein mesenchymal transition breast-cancer expression invasiveness progression carcinoma tumors cells lung | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrinology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrinology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology | |
pubs.volume | 33 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Endocrinology | en_US |
dc.contributor.icrauthor | Gevensleben, Heidrun | en |